| Dr Hagop Jack Keleshian, DO | |
|
201 Independence Ste 225, Columbus, MS 39710-5300 | |
| (626) 434-2237 | |
| Not Available |
| Full Name | Dr Hagop Jack Keleshian |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 11 Years |
| Location | 201 Independence Ste 225, Columbus, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326381468 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 25027 (Mississippi) | Secondary |
| 207Q00000X | Family Medicine | E-14904 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Magnolia Hospital | Magnolia, AR | Hospital |
| Tyler Holmes Memorial Hospital Cah | Winona, MS | Hospital |
| Helena Regional Medical Center | Helena, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Correct Care, Inc. | 8628980992 | 68 |
| Correct Care, Inc. | 8628980992 | 68 |
| Arkansas Emergency Staffing Solutions Inc | 3274681341 | 32 |
| Emergency Staffing Solutions Region Iii | 3375721707 | 13 |
| East Arkansas Emergency Physicians Pllc | 5698909067 | 22 |
| Helena Emergency Physicians Pllc | 9830245612 | 5 |
News Archive
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2011.
Pierre Foods, Inc. today officially unveiled Smart Picks—its new line of more nutritious school menu options—at the School Nutrition Association's Annual National Conference, giving students across the nation a reason to look forward to cafeteria lunches this coming fall. While other food manufacturers have committed to offering students more nutritious meal options in the coming two to five years, Smart Picks will be ready to serve in cafeterias when school begins next month.
Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.
The United States Agency for International Development (USAID) has awarded a five-year grant, Strengthening Health Outcomes through the Private Sector, to Abt Associates, Inc. Sub-recipients under the grant are Banyan Global, Jhpiego, Marie Stopes International, the Monitor Group, and O'Hanlon Health Consulting, LLC.
› Verified 1 days ago
| Entity Name | South Sunflower County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184679292 PECOS PAC ID: 6709771637 Enrollment ID: O20040218000979 |
News Archive
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2011.
Pierre Foods, Inc. today officially unveiled Smart Picks—its new line of more nutritious school menu options—at the School Nutrition Association's Annual National Conference, giving students across the nation a reason to look forward to cafeteria lunches this coming fall. While other food manufacturers have committed to offering students more nutritious meal options in the coming two to five years, Smart Picks will be ready to serve in cafeterias when school begins next month.
Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.
The United States Agency for International Development (USAID) has awarded a five-year grant, Strengthening Health Outcomes through the Private Sector, to Abt Associates, Inc. Sub-recipients under the grant are Banyan Global, Jhpiego, Marie Stopes International, the Monitor Group, and O'Hanlon Health Consulting, LLC.
› Verified 1 days ago
| Entity Name | Copiah County Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588667281 PECOS PAC ID: 2062583487 Enrollment ID: O20130211000504 |
News Archive
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2011.
Pierre Foods, Inc. today officially unveiled Smart Picks—its new line of more nutritious school menu options—at the School Nutrition Association's Annual National Conference, giving students across the nation a reason to look forward to cafeteria lunches this coming fall. While other food manufacturers have committed to offering students more nutritious meal options in the coming two to five years, Smart Picks will be ready to serve in cafeterias when school begins next month.
Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.
The United States Agency for International Development (USAID) has awarded a five-year grant, Strengthening Health Outcomes through the Private Sector, to Abt Associates, Inc. Sub-recipients under the grant are Banyan Global, Jhpiego, Marie Stopes International, the Monitor Group, and O'Hanlon Health Consulting, LLC.
› Verified 1 days ago
| Entity Name | Correct Care, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215987441 PECOS PAC ID: 8628980992 Enrollment ID: O20131122000662 |
News Archive
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2011.
Pierre Foods, Inc. today officially unveiled Smart Picks—its new line of more nutritious school menu options—at the School Nutrition Association's Annual National Conference, giving students across the nation a reason to look forward to cafeteria lunches this coming fall. While other food manufacturers have committed to offering students more nutritious meal options in the coming two to five years, Smart Picks will be ready to serve in cafeterias when school begins next month.
Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.
The United States Agency for International Development (USAID) has awarded a five-year grant, Strengthening Health Outcomes through the Private Sector, to Abt Associates, Inc. Sub-recipients under the grant are Banyan Global, Jhpiego, Marie Stopes International, the Monitor Group, and O'Hanlon Health Consulting, LLC.
› Verified 1 days ago
| Entity Name | Boa Vida Hospital Of Aberdeen Ms Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710405741 PECOS PAC ID: 0244505840 Enrollment ID: O20171128003460 |
News Archive
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2011.
Pierre Foods, Inc. today officially unveiled Smart Picks—its new line of more nutritious school menu options—at the School Nutrition Association's Annual National Conference, giving students across the nation a reason to look forward to cafeteria lunches this coming fall. While other food manufacturers have committed to offering students more nutritious meal options in the coming two to five years, Smart Picks will be ready to serve in cafeterias when school begins next month.
Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.
The United States Agency for International Development (USAID) has awarded a five-year grant, Strengthening Health Outcomes through the Private Sector, to Abt Associates, Inc. Sub-recipients under the grant are Banyan Global, Jhpiego, Marie Stopes International, the Monitor Group, and O'Hanlon Health Consulting, LLC.
› Verified 1 days ago
| Entity Name | Leake Emergency Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669028130 PECOS PAC ID: 4486985256 Enrollment ID: O20191009000078 |
News Archive
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2011.
Pierre Foods, Inc. today officially unveiled Smart Picks—its new line of more nutritious school menu options—at the School Nutrition Association's Annual National Conference, giving students across the nation a reason to look forward to cafeteria lunches this coming fall. While other food manufacturers have committed to offering students more nutritious meal options in the coming two to five years, Smart Picks will be ready to serve in cafeterias when school begins next month.
Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.
The United States Agency for International Development (USAID) has awarded a five-year grant, Strengthening Health Outcomes through the Private Sector, to Abt Associates, Inc. Sub-recipients under the grant are Banyan Global, Jhpiego, Marie Stopes International, the Monitor Group, and O'Hanlon Health Consulting, LLC.
› Verified 1 days ago
| Entity Name | Yazoo Emergency Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447806914 PECOS PAC ID: 0749511574 Enrollment ID: O20191009002380 |
News Archive
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2011.
Pierre Foods, Inc. today officially unveiled Smart Picks—its new line of more nutritious school menu options—at the School Nutrition Association's Annual National Conference, giving students across the nation a reason to look forward to cafeteria lunches this coming fall. While other food manufacturers have committed to offering students more nutritious meal options in the coming two to five years, Smart Picks will be ready to serve in cafeterias when school begins next month.
Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.
The United States Agency for International Development (USAID) has awarded a five-year grant, Strengthening Health Outcomes through the Private Sector, to Abt Associates, Inc. Sub-recipients under the grant are Banyan Global, Jhpiego, Marie Stopes International, the Monitor Group, and O'Hanlon Health Consulting, LLC.
› Verified 1 days ago
| Entity Name | Relias Emergency Medicine Specialists Of Amory, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265074769 PECOS PAC ID: 4486088853 Enrollment ID: O20191218002639 |
News Archive
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2011.
Pierre Foods, Inc. today officially unveiled Smart Picks—its new line of more nutritious school menu options—at the School Nutrition Association's Annual National Conference, giving students across the nation a reason to look forward to cafeteria lunches this coming fall. While other food manufacturers have committed to offering students more nutritious meal options in the coming two to five years, Smart Picks will be ready to serve in cafeterias when school begins next month.
Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.
The United States Agency for International Development (USAID) has awarded a five-year grant, Strengthening Health Outcomes through the Private Sector, to Abt Associates, Inc. Sub-recipients under the grant are Banyan Global, Jhpiego, Marie Stopes International, the Monitor Group, and O'Hanlon Health Consulting, LLC.
› Verified 1 days ago
| Entity Name | Relias Hospitalist Medicine Specialists Of West Point Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821638578 PECOS PAC ID: 4688002322 Enrollment ID: O20200312000355 |
News Archive
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2011.
Pierre Foods, Inc. today officially unveiled Smart Picks—its new line of more nutritious school menu options—at the School Nutrition Association's Annual National Conference, giving students across the nation a reason to look forward to cafeteria lunches this coming fall. While other food manufacturers have committed to offering students more nutritious meal options in the coming two to five years, Smart Picks will be ready to serve in cafeterias when school begins next month.
Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.
The United States Agency for International Development (USAID) has awarded a five-year grant, Strengthening Health Outcomes through the Private Sector, to Abt Associates, Inc. Sub-recipients under the grant are Banyan Global, Jhpiego, Marie Stopes International, the Monitor Group, and O'Hanlon Health Consulting, LLC.
› Verified 1 days ago
| Entity Name | Relias Emergency Medicine Specialists Of West Point, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275172736 PECOS PAC ID: 0042648594 Enrollment ID: O20200316000656 |
News Archive
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2011.
Pierre Foods, Inc. today officially unveiled Smart Picks—its new line of more nutritious school menu options—at the School Nutrition Association's Annual National Conference, giving students across the nation a reason to look forward to cafeteria lunches this coming fall. While other food manufacturers have committed to offering students more nutritious meal options in the coming two to five years, Smart Picks will be ready to serve in cafeterias when school begins next month.
Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.
The United States Agency for International Development (USAID) has awarded a five-year grant, Strengthening Health Outcomes through the Private Sector, to Abt Associates, Inc. Sub-recipients under the grant are Banyan Global, Jhpiego, Marie Stopes International, the Monitor Group, and O'Hanlon Health Consulting, LLC.
› Verified 1 days ago
| Entity Name | Relias Hospitalist Medicine Specialists Of Pontotoc Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972189330 PECOS PAC ID: 0143629592 Enrollment ID: O20210604001444 |
News Archive
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2011.
Pierre Foods, Inc. today officially unveiled Smart Picks—its new line of more nutritious school menu options—at the School Nutrition Association's Annual National Conference, giving students across the nation a reason to look forward to cafeteria lunches this coming fall. While other food manufacturers have committed to offering students more nutritious meal options in the coming two to five years, Smart Picks will be ready to serve in cafeterias when school begins next month.
Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.
The United States Agency for International Development (USAID) has awarded a five-year grant, Strengthening Health Outcomes through the Private Sector, to Abt Associates, Inc. Sub-recipients under the grant are Banyan Global, Jhpiego, Marie Stopes International, the Monitor Group, and O'Hanlon Health Consulting, LLC.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Hagop Jack Keleshian, DO 201 Independence Ste 225, Columbus, MS 39710-5300 Ph: (626) 434-2237 | Dr Hagop Jack Keleshian, DO 201 Independence Ste 225, Columbus, MS 39710-5300 Ph: (626) 434-2237 |
News Archive
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2011.
Pierre Foods, Inc. today officially unveiled Smart Picks—its new line of more nutritious school menu options—at the School Nutrition Association's Annual National Conference, giving students across the nation a reason to look forward to cafeteria lunches this coming fall. While other food manufacturers have committed to offering students more nutritious meal options in the coming two to five years, Smart Picks will be ready to serve in cafeterias when school begins next month.
Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.
The United States Agency for International Development (USAID) has awarded a five-year grant, Strengthening Health Outcomes through the Private Sector, to Abt Associates, Inc. Sub-recipients under the grant are Banyan Global, Jhpiego, Marie Stopes International, the Monitor Group, and O'Hanlon Health Consulting, LLC.
› Verified 1 days ago
Dr. Gerald Turner, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 56 Dutch Ln, Columbus, MS 39702 Phone: 662-329-3808 Fax: 662-329-3873 | |
Robert L Buckley, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 56 Dutch Ln, Columbus, MS 39702 Phone: 662-329-3808 Fax: 662-329-3873 | |
John Stanback, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4508 Highway 45 N, Columbus, MS 39705 Phone: 662-328-9702 Fax: 662-328-0954 | |
Josiah P Becker, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 201 Independence, Columbus, MS 39710 Phone: 662-434-2273 | |
Dr. Kevin Petronela Juozapavicius, D.O., MS, BS Family Medicine Medicare: Medicare Enrolled Practice Location: 201 Independence, Columbus Afb, Columbus, MS 39710 Phone: 662-434-2273 | |
Dr. Megan R Moran, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2520 5th St N, Columbus, MS 39705 Phone: 662-244-2042 Fax: 662-244-2041 |